Project Grant HT94252510515
Award Date
6/15/25
Completion Date
6/14/28
Dollars Obligated
$2.2M
Federal Agency
Defense Health Agency
Awardee
Mainehealth (MAYKB1LWD5U9)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Portland, ME 04101, USA
Similar Awards
The Defense Health Agency awarded a $2,371,837 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Medstar Health Research Institute Inc. to conduct a pilot multicenter study on resuscitation with enteral fluids. The grant will fund a 3-year research project starting July 2024 that focuses on transforming healthcare for military service members and the broader public. The grant includes a sub-award to Louisiana State University Health Sciences Center New...
The federal Project Grant award of $818,337.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The funding supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. Specifically, the award to Vascular Perfusion Solutions Inc. will support research and development of the "Extended Limb Stasis in the Encore Tissue Preservation...
This federal Project Grant award from the U.S. Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $516,000.00 to Mainehealth, a non-profit healthcare system in Portland, Maine, to develop a novel ovarian cancer treatment targeting a unique extracellular matrix component using an antibody conjugate. This 2-year research project, which commenced on May 15, 2024, aims to advance innovative cancer treatment approaches with...
This federal Project Grant award of $1,991,326.00, awarded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) aimed at suppressing barrier antimicrobial defenses in the context of trauma. The 3-year grant, with a performance period from September 30, 2024 to September 29, 2027, will enable Bidmc, a prominent academic medical center in...
This federal Project Grant award of $2,399,874.00 from the Defense Health Agency, administered under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The award to Vanderbilt University Medical Center, a prominent academic medical center and non-profit healthcare provider, will fund research to decode the inflammatory mechanisms and...
The federal Project Grant award of $2,013,978.00 to New York University School of Medicine was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research focused on "Targeting RAGE After Particulate Matter Exposure: Metabolic Dysregulation and Disease Mitigation." The research aims to investigate innovative approaches to disease prevention, diagnosis, treatment, and management, with a...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $7,693,599 project grant to the University of Texas Health Science Center at Houston (UTHealth). The award, with a period of performance from Sep 15, 2023 to Sep 14, 2027, will fund research to study "Trauma-Induced Coagulopathy and the Blood-Brain Barrier: Impact of Resuscitation." As the prime grantee, UTHealth will leverage its expertise in biomedical research, clinical...
The Department of the Army Medical Command awarded a $1,999,583 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program to IRR Inc. in Santa Barbara, CA. The grant will fund an early-stage proof-of-concept study of a fixed-dose combination therapy in a high-fidelity porcine model of severe polytrauma. The 2-year project, running from July 1, 2025 to June 30, 2027, aims to advance medical solutions for the battlefield and transform healthcare for...
The federal Project Grant award, ID HT94252410512, in the amount of $1,008,313.00, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The grant was awarded to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution, to support advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader...
The Defense Health Agency awarded Epicentrx Inc. a $385,536 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program. The funding supports the development and translation of a multimodal therapeutic agent and medical countermeasure for the treatment of military-related toxic exposures. The project will be conducted over a 3-year period from September 1, 2024 to August 31, 2027. The research aims to transform healthcare for military service members and...